I am a
Home I AM A Search Login

Papers of the Week


Papers: 12 Oct 2024 - 18 Oct 2024


2024 Oct 14


Int Immunopharmacol


39405941


143


Pt 1

Poly-(ADP-ribose) polymerase 1-modulated production of CXCL1 in the dorsal root ganglion and spinal dorsal horn exacerbated inflammatory pain in rats.

Authors

Bai L, Gao Y, Li L, Liang Z, Qiao Y, Wang X, Yv L, Yang JJ, Xu JT

Abstract

Poly (ADP-ribose) polymerase 1 (PARP-1) serves as a transcriptional co-regulator and has been playing an important role in various inflammatory diseases. In the present study, we investigated the role and underlying mechanisms of action of PARP-1 in inflammatory pain. Intraplantar injection of complete Freund’s adjuvant (CFA) was administered to the rats to induce inflammatory pain. Immunofluorescence, Western blotting, co-immunoprecipitation, and chromatin immunoprecipitation-quantitative polymerase chain reaction were performed to investigate the underlying mechanisms. Our results showed that CFA injection led to an increase in the production and activation of PARP-1 in both the L4/5 dorsal root ganglions (DRGs) and the spinal dorsal horn. Repeated intrathecal injections of Tiq-A or 5-AIQ, two specific inhibitors of PARP-1, and microinjections of AAV-PARP-1 shRNA into the L5 DRG or L5 spinal dorsal horn partially prevented the development of inflammatory pain. The established inflammatory pain was attenuated by a single bolus of intrathecal injection of Tiq-A or 5-AIQ on day 7 after the CFA injection. The CFA-induced mechanical allodynia and thermal hyperalgesia in female rats were alleviated by repeated intrathecal injections of Tiq-A. Moreover, repeated intrathecal injections of 5-AIQ inhibited the binding of NF-κB with CXCL1 promoter and reduced the production of CXCL1 in both the L4/5 DRGs and L4-6 spinal dorsal horns following CFA injection. Collectively, our results indicate that CFA-induced upregulation of PARP-1 by promoting CXCL1 expression in the DRG and probably in the spinal dorsal horn contributes to the pathogenesis of inflammatory pain. Thus, PARP-1 may be a potential pharmaceutical target for the treatment of inflammatory pain.